Cell No. : Cell Name
RCB1460 : PCM6
update : 2024/09/09
|
| Comment | Human myeloma cell. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Minami(Hirose), Rumi
|
| Originator |
Takahira, Hiroyuki
|
| Year of deposit |
1998
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Female
|
| Age at sampling |
60 years
|
| Tissue |
peripheral blood
|
| Disease name |
myeloma
|
| Classification |
cancer
|
| Year of origin |
1992
|
| History |
originator -> Minami(Hirose), R.
|
| Memo_1 |
Mycoplasma was eliminated with MC-210 by the depositor.
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_4666
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
| Culture method |
|
浮遊細胞の培養に関する一般的な注意(Japanese)
|
| Culture medium |
|
McCoy's 5A + 20% FBS + 30U/ml human IL-6
|
| Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 2 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Virus (HIV) |
|
LT 400
|
| Virus (HTLV-1) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
44(50)
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
3
|
| User's Publication |
|
6968
Suzuki T, Sato Y, Sano K, Arashiro T, Katano H, Nakajima N, Shimojima M, Kataoka M, Takahashi K, Wada Y, Morikawa S, Fukushi S, Yoshikawa T, Saijo M, Hasegawa H.
Severe fever with thrombocytopenia syndrome virus targets B cells in lethal human infections.
J Clin Invest
2020
130(2):799-812
PubMed ID: 31904586
DOI: 10.1172/JCI129171
|
|
18240
Nara M, Teshima K, Watanabe A, Ito M, Iwamoto K, Kitabayashi A, Kume M, Hatano Y, Takahashi N, Iida S, Sawada K, Tagawa H.
Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells
PLoS One
2013
8(3):e56954
PubMed ID: 23469177
DOI: 10.1371/journal.pone.0056954
|
|
7595
Harada Y, Ishii I, Hatake K, Kasahara T.
Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3.
Cancer Lett.
2012
319:83-8
PubMed ID: 22210382
DOI: 10.1016/j.canlet.2011.12.034
|
Back
Top
CELL BANK Website
